Macrogenics INC 10-Q quarterly reports

MacroGenics reports a 58% revenue increase in Q1 2026 driven by contract manufacturing and royalty revenue, alongside a 12% decrease in R&D expenses.

MacroGenics reported a net income of $16.8 million for Q3 2025, a significant decrease from $56.3 million in Q3 2024, primarily due to milestone timing and the sale of MARGENZA rights, while extending its cash runway into late 2027.

MacroGenics reported a reduced net loss and increased collaboration revenue in Q2 2025, extending its financial runway through the first half of 2027.

MacroGenics' Q1 2025 financial results show increased revenue driven by collaborative agreements and contract manufacturing, despite a net loss.

MacroGenics' Q3 2024 results show a significant revenue increase due to a $100 million milestone payment from Incyte, alongside the announcement of the sale of MARGENZA to TerSera.

MacroGenics' second quarter 2024 results show a decrease in revenue compared to the same period last year, primarily due to reduced collaboration revenue, while research and development expenses increased.

MacroGenics' first quarter 2024 revenue decreased significantly compared to the same period last year, primarily due to the timing of milestone payments, while product sales saw an increase.